Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1403700 | 0.89 | LMNA (0.39) | ALDH1A1KDM4ELMNACYP1A2HIF1A | |
| SCHEMBL20774449 | 0.83 | ALDH1A1 (0.33) | ALDH1A1MEN1KMT2ANPSR1ASAH1 | |
| SCHEMBL27806551 | 0.83 | NR1I2 (0.39) | ALDH1A1CYSLTR2CYSLTR1CSNK1ENAAA | |
| SCHEMBL3819879 | 0.82 | RIPK1 (0.34) | ALDH1A1KDM4ELMNARIPK1 | |
| SCHEMBL27306885 | 0.82 | LMNA (0.57) | ALDH1A1KDM4ELMNACYP1A2HIF1A | |
| SCHEMBL20853886 | 0.81 | ALDH1A1 (0.35) | ALDH1A1MEN1KMT2ANPSR1ASAH1 | |
| SCHEMBL20774543 | 0.81 | ALDH1A1 (0.35) | ALDH1A1MEN1KMT2ANPSR1ASAH1 | |
| SCHEMBL20853875 | 0.81 | ALDH1A1 (0.35) | ALDH1A1MEN1KMT2ANPSR1ASAH1 | |
| SCHEMBL20854124 | 0.81 | ALDH1A1 (0.35) | ALDH1A1MEN1KMT2ANPSR1ASAH1 | |
| SCHEMBL20774452 | 0.81 | ALDH1A1 (0.35) | ALDH1A1MEN1KMT2ANPSR1ASAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5025028-A | Asthma | BOEHRINGER MANNHEIM GMBH (DE) | 1991-06-18 | — | — | US | claimed |
| US-4906666-A | Hydroxamic acids and pharmaceutical compositions containing them, and anti-allergic use thereof | BOEHRINGER MANNHEIM GMBH (DE) | 1990-03-06 | — | — | US | claimed |
| EP-2046714-B1 | Cyclopentane derivatives as antiglaucoma agents | ALLERGAN INC (US) | 2015-12-09 | — | — | EP | disclosed |
| EP-2043993-B1 | CYCLOPENTANE DERIVATIVES AS ANTIGLAUCOMA AGENTS | ALLERGAN INC (US) | 2015-07-01 | — | — | EP | disclosed |
| EP-2069295-B1 | SUBSTITUTED CYCLOPENTANE DERIVATIVES AS THERAPEUTIC AGENTS | ALLERGAN INC (US) | 2013-12-18 | — | — | EP | disclosed |
| US-8569349-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2291353-B1 | THERAPEUTIC PROSTAGLANDIN COMPOUNDS USED AS OCULAR HYPOTENSIVE AGENTS | ALLERGAN INC (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20130005767-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-8338637-B2 | Glaucoma; prostaglandin receptor modulators; cyclopentyl compounds such as 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid | ALLERGAN, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8252788-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| EP-2114875-B1 | SUBSTITUTED ARYLCYLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN INC (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20080015231-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2008-01-17 | — | — | US | disclosed |
| WO-2008008700-A2 | SUBSTITUTED CYCLOPENTANE DERIVATIVES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008701-A2 | SUBSTITUTED CYCLOPENTANE DERIVATIVES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20080015219-A1 | Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists; acid-functional aryl substituted cyclopentanone or hydroxycyclopentane compounds | ALLERGAN, INC. | 2008-01-17 | — | — | US | disclosed |
| WO-2008008660-A2 | CYCLOPENTANE DERIVATIVES AS ANTIGLAUCOMA AGENTS | ALLERGAN, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2007149829-A2 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20070293561-A1 | 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid; Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists | ALLERGAN, INC. | 2007-12-20 | — | — | US | disclosed |
| US-4625034-A | 1,2-Dihydro; 1,2,3,4-tetrahydro; 5,8 dihydro; and 5,6,7,8-tetrahydroquinoline derivatives | USV PHARMACEUTICAL CORP. (US) | 1986-11-25 | — | — | US | disclosed |
| EP-0190722-A2 | Dihydro and tetrahydroquinoline derivatives | USV PHARMACEUTICAL CORPORATION (US) | 1986-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293561-A1 | 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid; Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists | PTGIR, PTGIS, PTGER2 | ALDH1A1 883/4885KDM4E 2886/4885LMNA 3367/4885 |
| US-20130005767-A1 | THERAPEUTIC COMPOUNDS | THPO, HLA-C, PIGO | ALDH1A1 1004/4885KDM4E 4700/4885LMNA 3173/4885 |
| US-20080015219-A1 | Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists; acid-functional aryl substituted cyclopentanone or hydroxycyclopentane compounds | PTGER2, PTGER1, PTGS2 | ALDH1A1 655/4885KDM4E 3080/4885LMNA 2290/4885 |
| US-20080015231-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, COXFA4L2 | ALDH1A1 438/4885KDM4E 4067/4885LMNA 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.